



REVISTA BRASILEIRA DE REUMATOLOGIA

www.reumatologia.com.br



SOCIEDADE BRASILEIRA
DE REUMATOLOGIA

Erratum

Erratum of Guidelines for the drug treatment of rheumatoid arthritis

Licia Maria Henrique da Mota^{a,*}, Bóris Afonso Cruz^a, Claiton Viegas Brenol^a, Ivânio Alves Pereira^a, Lucila Stange Rezende-Fronza^a, Manoel Barros Bertolo^a, Max Vitor Carioca Freitas^a, Nilzio Antônio da Silva^a, Paulo Louzada-Junior^a, Rina Dalva Neubarth Giorgi^a, Rodrigo Aires Corrêa Lima^a, Wanderley Marques Bernardo^b, Geraldo da Rocha Castelar Pinheiro^a

^aSociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology), São Paulo, SP, Brazil

^bAssociação Médica Brasileira (Brazilian Medical Association), São Paulo, SP, Brazil

In the original article, "Guidelines for the drug treatment of rheumatoid arthritis" (Rev Bras Reumatol 2013;53(2):158-183), where it reads:

Guidelines for the drug treatment of rheumatoid arthritis

Sociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology)

Projeto Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brazil

Participants

Licia Maria Henrique da Mota^{}, Bóris Afonso Cruz, Claiton Viegas Brenol, Ivânio Alves Pereira, Lucila Stange Rezende-Fronza, Manoel Barros Bertolo, Max Vitor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada-Junior, Rina Dalva Neubarth Giorgio, Rodrigo Aires Corrêa Lima, Wanderley Marques Bernardo, Geraldo da Rocha Castelar Pinheiro*

It should read:

Guidelines for the drug treatment of rheumatoid arthritis

Licia Maria Henrique da Mota^{a,}, Bóris Afonso Cruz^a, Claiton Viegas Brenol^a, Ivânio Alves Pereira^a, Lucila Stange Rezende-Fronza^a, Manoel Barros Bertolo^a, Max Vitor Carioca Freitas^a, Nilzio Antônio da Silva^a, Paulo Louzada-Junior^a, Rina Dalva Neubarth Giorgi^a, Rodrigo Aires Corrêa Lima^a, Wanderley Marques Bernardo^b, Geraldo da Rocha Castelar Pinheiro^a*

^aSociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology), São Paulo, SP, Brazil

^bAssociação Médica Brasileira (Brazilian Medical Association), São Paulo, SP, Brazil

At page 169, where it reads:

RA patients can be treated with anti-TNF biologic DMARDs, including adalimumab (40 mg SC every two weeks), certolizumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 mg every two weeks thereafter or 400 mg every four weeks, or monthly), etanercept (50 mg SC every two weeks), golimumab (50 SC every four weeks or monthly), or infliximab (3 mg/kg IV at weeks 0, 2 and 6 and every 8 weeks thereafter).

* Corresponding author.

E-mail: liciamhmota@gmail.com (L.M.H Mota).

it should read:

RA patients can be treated with anti-TNF biologic DMARDs, including adalimumab (40 mg SC every two weeks), certolizumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 mg every two weeks thereafter or 400 mg every four weeks, or monthly), etanercept (50 mg SC weekly), golimumab (50 SC every four weeks or monthly), or infliximab (3 mg/kg IV at weeks 0, 2 and 6 and every 8 weeks thereafter).

At page 172, table 5 [Portuguese edition only], where it reads:

Tabela 5 – Medidas de ACR50 e DAS-28 expressas pelo benefício estimado por meio do Número Necessário para Tratar (NNT).

Índice	Estado da atividade de doença	Pontos de corte	NNT	
			ACR50	DAS-28
Golimumabe	50 mg	24 semanas	10	7
Adalimumabe	40 mg	52 semanas	3	5
Etanercept	50 mg	52 semanas	5	5
Infliximabe	3 mg/kg	22 semanas	5	6
Certolizumabe	200 mg	52 semanas	3	6
Rituximabe	1000 mg	52 semanas	6	5
Tocilizumabe	8 mg/kg	24 semanas	3	4
Abatacepte	500-1000 mg	52 semanas	11	10

It should read:

Tabela 5 – Medidas de ACR50 e DAS-28 expressas pelo benefício estimado por meio do Número Necessário para Tratar (NNT).

Biológico	Dose	Tempo	NNT	
			ACR50	DAS-28
Golimumabe	50 mg	24 semanas	10	7
Adalimumabe	40 mg	52 semanas	3	5
Etanercept	50 mg	52 semanas	5	5
Infliximabe	3 mg/kg	22 semanas	5	6
Certolizumabe	200 mg	52 semanas	3	6
Rituximabe	1000 mg	52 semanas	6	5
Tocilizumabe	8 mg/kg	24 semanas	3	4
Abatacepte	500-1000 mg	52 semanas	11	10